Tumour morphology of early-onset breast cancers predicts breast cancer risk for first-degree relatives: the Australian Breast Cancer Family Registry

Breast Cancer Research

Volumn 14, Issue 4, 2012, Pages

  Dite, Gillian S ^a   Makalic, Enes ^a   Schmidt, Daniel F ^a   Giles, Graham G ^a,b   Hopper, John L ^a   Southey, Melissa C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CANCER EPIDEMIOLOGY CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; AUSTRALIA; BREAST CANCER; CANCER REGISTRY; CANCER RISK; CANCER SUSCEPTIBILITY; DNA METHYLATION; FEMALE; GENE MUTATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MORPHOLOGY; ONSET AGE; PROMOTER REGION; RELATIVE; STANDARDIZED INCIDENCE RATIO; TUMOR SUPPRESSOR GENE; BREAST NEOPLASMS; CANCER GRADING; CANCER STAGING; FAMILY; GENETICS; MUTATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK; YOUNG ADULT;

ADULT; AGE OF ONSET; AUSTRALIA; BREAST NEOPLASMS; DNA METHYLATION; FAMILY; FEMALE; GENES, BRCA1; HUMANS; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK; YOUNG ADULT;

EID: 84865338366     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3248     Document Type: Article

References (39)

1. Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 1997, 71:800-809. 10.1002/(SICI)1097-0215(19970529)71:5<800::AID-IJC18>3.0.CO;2-B, 9180149.
2. Collaborative Group on Hormonal Factors in Breast Cancer Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001, 358:1389-1399. Collaborative Group on Hormonal Factors in Breast Cancer.
3. Dite GS, Jenkins MA, Southey MC, Hocking JS, Giles GG, McCredie MR, Venter DJ, Hopper JL. Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. J Natl Cancer Inst 2003, 95:448-457. 10.1093/jnci/95.6.448, 12644538.
4. Loman N, Bladström A, Johannsson O, Borg A, Olsson H. Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status. Breast Cancer Res 2003, 5:R175-R186. 10.1186/bcr632, 314401, 14580253.
5. Lee JS, John EM, McGuire V, Felberg A, Ostrow KL, DiCioccio RA, Li FP, Miron A, West DW, Whittemore AS. Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations. Cancer Epidemiol Biomarkers Prev 2006, 15:359-363. 10.1158/1055-9965.EPI-05-0687, 16492929.
6. Dite GS, Whittemore AS, Knight JA, John EM, Milne RL, Andrulis IL, Southey MC, McCredie MR, Giles GG, Miron A, Phipps AI, West DW, Hopper JL. Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations. Br J Cancer 2010, 103:1103-1108. 10.1038/sj.bjc.6605876, 2965877, 20877337.
7. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987, 316:1289-1294. 10.1056/NEJM198705213162101, 3574400.
8. Li FP, Fraumeni JF. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?. Ann Intern Med 1969, 71:747-752.
9. Lalloo F, Varley J, Moran A, Ellis D, O'Dair L, Pharoah P, Antoniou A, Hartley R, Shenton A, Seal S, Bulman B, Howell A, Evans DG. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 2006, 42:1143-1150. 10.1016/j.ejca.2005.11.032, 16644204.
10. Mouchawar J, Korch C, Byers T, Pitts TM, Li E, McCredie MR, Giles GG, Hopper JL, Southey MC. Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res 2010, 70:4795-4800. 10.1158/0008-5472.CAN-09-0851, 3228832, 20501846.
11. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, Seal S, Ghoussaini M, Hines S, Healey CS, Hughes D, Warren-Perry M, Tapper W, Eccles D, Evans DG, , Hooning M, Schutte M, van den Ouweland A, Houlston R, Ross G, Langford C, Pharoah PD, Stratton MR, Dunning AM, Rahman N, Easton DF. Breast Cancer Susceptibility Collaboration (UK) Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 2010, 42:504-507. 10.1038/ng.586, 20453838, Breast Cancer Susceptibility Collaboration (UK).
12. Southey MC, Ramus SJ, Dowty JG, Smith LD, Tesoriero AA, Wong EE, Dite GS, Jenkins MA, Byrnes GB, Winship I, Phillips KA, Giles GG, Hopper JL. Morphological predictors of BRCA1 germline mutations in young women with breast cancer. Br J Cancer 2011, 104:903-909. 10.1038/bjc.2011.41, 3065278, 21343941.
13. Wong EM, Southey MC, Fox SB, Brown MA, Dowty JG, Jenkins MA, Giles GG, Hopper JL, Dobrovic A. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res 2011, 4:23-33.
14. Hopper JL, Giles GG, McCredie MRE, Boyle P. Background, rationale and protocol for a case-control-family study of breast cancer. Breast 1994, 3:79-86.
15. McCredie MRE, Dite GS, Giles GG, Hopper JL. Breast cancer in Australian women under the age of 40. Cancer Causes Control 1998, 9:189-198. 10.1023/A:1008886328352, 9578296.
16. Hopper JL, Chenevix-Trench G, Jolley D, Dite GS, Jenkins MA, Venter DJ, McCredie MR, Giles GG. Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS). J Natl Cancer Inst Monogr 1999, 26:95-100.
17. Armes JE, Egan AJ, Southey MC, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 1998, 83:2335-2345. 10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.0.CO;2-N, 9840533.
18. Longacre TA, Ennis M, Quenneville LA, Bane AL, Bleiweiss IJ, Carter BA, Catelano E, Hendrickson MR, Hibshoosh H, Layfield LJ, Memeo L, Wu H, O'Malley FP. Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Mod Pathol 2006, 19:195-207. 10.1038/modpathol.3800496, 16341153.
19. Page DL, Anderson TJ, Sakamoto G. Infiltrating carcinoma: major histological types. Diagnostic Histopathology of the Breast 1987, 193-235. Edinburgh: Churchill Livingstone, Page DL, Anderson TJ.
20. Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, Hutchins AM, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ. Distinct molecular pathogenesis of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 1999, 59:2011-2017.
21. McCredie MRE, Dite GS, Southey MC, Venter DJ, Giles GG, Hopper JL. Risk factors for breast cancer by oestrogen receptor and progesterone receptor status. Br J Cancer 2003, 89:1661-1663. 10.1038/sj.bjc.6601293, 2394423, 14583766.
22. Tavtigian SV, Oefner PJ, Babikyan D, Hartmann A, Healey S, Le Calvez-Kelm F, Lesueur F, Byrnes GB, Chuang SC, Forey N, Feuchtinger C, Gioia L, Hall J, Hashibe M, Herte B, McKay-Chopin S, Thomas A, Vallée MP, Voegele C, Webb PM, Whiteman DC, , Sangrajrang S, Hopper JL, Southey MC, Andrulis IL, John EM, Chenevix-Trench G. Australian Cancer Study; Breast Cancer Family Registries (BCFR); Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab) Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet 2009, 85:427-446. 10.1016/j.ajhg.2009.08.018, 2756555, 19781682, Australian Cancer Study; Breast Cancer Family Registries (BCFR); Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab).
23. Goldgar DE, Healey S, Dowty JG, Da Silva L, Chen X, Spurdle AB, Terry MB, Daly MJ, Buys SM, Southey MC, Andrulis I, John EM, , Khanna KK, Hopper JL, Oefner PJ, Lakhani S, Chenevix-Trench G. BCFR; kConFab Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res 2011, 13:R73. 10.1186/bcr2919, 3236337, 21787400, BCFR; kConFab.
24. Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X, Donn K, Cummings M, Nyholt D, Jenkins MA, Scott C, Pupo GM, Dörk T, Bendix R, Kirk J, Tucker K, McCredie MR, Hopper JL, Sambrook J, Mann GJ, Khanna KK. Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 2002, 94:205-215. Erratum in. J Natl Cancer Inst, 2002, 94:952, 10.1093/jnci/94.3.205, 11830610.
25. Bernstein JL, Teraoka S, Southey MC, Jenkins MA, Andrulis IL, Knight JA, John EM, Lapinski R, Wolitzer AL, Whittemore AS, West D, Seminara D, Olson ER, Spurdle AB, Chenevix-Trench G, Giles GG, Hopper JL, Concannon P. Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. Hum Mutat 2006, 27:1122-1128. 10.1002/humu.20415, 16958054.
26. Breslow NE, Day NE. Statistical Methods in Cancer Research. Volume II - The Design and Analysis of Cohort Studies 1987, Lyon, France: International Agency for Research on Cancer.
27. Park T, Casella G. The Bayesian lasso. J Amer Statistical Assoc 2008, 103:681-686.
28. Kyung M, Gill J, Ghosh M, Casella G. Penalized regression, standard errors, and Bayesian lassos. Bayesian Analysis 2010, 5:369-412.
29. StataCorp Stata Statistical Software: Release 11.0 2010, College Station, TX: StataCorp LP, StataCorp.
30. The MathWorks, Inc. MATLAB version 7.13.0 2011, Natick, Massachusetts: The MathWorks Inc, The MathWorks, Inc..
31. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Bignon YJ, Struewing JP, Spurr NK, Bishop DT, Klijn JG, Devilee P, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998, 90:1138-1145. 10.1093/jnci/90.15.1138, 9701363.
32. Lakhani SR, van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and P53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002, 20:2310-2318. 10.1200/JCO.2002.09.023, 11981002.
33. Jiang X, Castelao JE, Chavez-Uribe E, Fernandez Rodriguez B, Celeiro Muñoz C, Redondo CM, Peña Fernandez M, Novo Dominguez A, Pereira CD, Martínez ME, García-Caballero T, Fraga Rodriguez M, Antúnez J, Carracedo A, Forteza-Vila J, Gago-Dominguez M. Family history and breast cancer hormone receptor status in a Spanish cohort. PLoS One 2012, 7:e29459. 10.1371/journal.pone.0029459, 3253097, 22238615.
34. Lorenzo BJ, Hemminki K. Familial association of histology specific breast cancers with cancers at other sites. Int J Cancer 2004, 109:430-435. 10.1002/ijc.11713, 14961583.
35. Tutera AM, Sellers TA, Potter JD, Drinkard CR, Wiesner GL, Folsom AR. Association between family history of cancer and breast cancer defined by estrogen and progesterone receptor status. Genet Epidemiol 1996, 13:207-221. 10.1002/(SICI)1098-2272(1996)13:2<207::AID-GEPI6>3.0.CO;2-4, 8722747.
36. Ellberg C, Olsson H. Breast cancer patients with lobular cancer more commonly have a father than a mother diagnosed with cancer. BMC Cancer 2011, 11:497. 10.1186/1471-2407-11-497, 3241222, 22117567.
37. Martins FC, De S, Almendro V, Gönen M, Park SY, Blum JL, Herlihy W, Ethington G, Schnitt SJ, Tung N, Garber JE, Fetten K, Michor F, Polyak K. Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov 2012, 2:503-511. 10.1158/2159-8290.CD-11-0325, 22628410.
38. Masciari S, Dillon DA, Rath M, Robson M, Weitzel JN, Balmana J, Gruber SB, Ford JM, Euhus D, Lebensohn A, Telli M, Pochebit SM, Lypas G, Garber JE. Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat 2012, 133:1125-1130. 10.1007/s10549-012-1993-9, 22392042.
39. Flanagan JM, Cocciardi S, Waddell N, Johnstone CN, Marsh A, Henderson S, Simpson P, da Silva L, , Khanna K, Lakhani S, Boshoff C, Chenevix-Trench G. kConFab Investigators DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status. Am J Hum Genet 2010, 86:420-433. 10.1016/j.ajhg.2010.02.008, 2833389, 20206335, kConFab Investigators.